Topical Ocular Mecamylamine in Diabetic Macular Edema (DME)
Phase 2
Completed
- Conditions
- Diabetic Macular Edema
- Registration Number
- NCT00536692
- Lead Sponsor
- CoMentis
- Brief Summary
This is an open-label study evaluating the safety and tolerability of topical ocular mecamylamine given twice a day in patients with diabetic macular edema (DME). Patients will be treated for 12 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- macular edema due to diabetic retinopathy
Exclusion Criteria
- vision loss from other ocular disease
- intraocular surgery within 3 months
- intraocular anti-VEGF or steroids within 3 months
- HbA1c >12
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
East Bay Retina Consultants, Inc.
🇺🇸Oakland, California, United States
Johns Hopkins School of Medicine / Wilmer Eye Institute
🇺🇸Baltimore, Maryland, United States
Ophthalmic Consultants of Boston
🇺🇸Boston, Massachusetts, United States
East Bay Retina Consultants, Inc.🇺🇸Oakland, California, United States